1
Country: USA | Funding: $231M
Chai Discovery develops AI models that predict and reprogram biochemical molecule interactions. Chai’s goal is to shorten the drug development timeline so that potential new medicines enter first-in-human studies and reach the market quicker. It can design molecules that have needed properties and tackle challenging targets that have been out of reach. The team has already used its flagship model Chai 2 to develop monoclonal antibodies aimed against tough-to-drug targets, and (accoring to the company) the new designs have properties similar to known antibody drugs.
Chai Discovery develops AI models that predict and reprogram biochemical molecule interactions. Chai’s goal is to shorten the drug development timeline so that potential new medicines enter first-in-human studies and reach the market quicker. It can design molecules that have needed properties and tackle challenging targets that have been out of reach. The team has already used its flagship model Chai 2 to develop monoclonal antibodies aimed against tough-to-drug targets, and (accoring to the company) the new designs have properties similar to known antibody drugs.
2
Country: USA | Funding: $305M
Parabilis Medicines has developed drug discovery platform for alpha-helical-linked peptides, primarily composed of specially selected non-canonical amino acids. Using this platform, Parabilis has assembled a large set of non-canonical amino acids and has hundreds of proprietary linkers for stabilizing peptides in the alpha-helical conformation. To fully exploit this diversity, the company has developed a suite of specialized experimental systems that can generate massive amounts of data on a wide range of drug properties, providing both input for building artificial intelligence models and serving as a high-throughput platform for empirically validating model predictions. As a pilot project, the company is advancing a drug against desmoid tumors.
Parabilis Medicines has developed drug discovery platform for alpha-helical-linked peptides, primarily composed of specially selected non-canonical amino acids. Using this platform, Parabilis has assembled a large set of non-canonical amino acids and has hundreds of proprietary linkers for stabilizing peptides in the alpha-helical conformation. To fully exploit this diversity, the company has developed a suite of specialized experimental systems that can generate massive amounts of data on a wide range of drug properties, providing both input for building artificial intelligence models and serving as a high-throughput platform for empirically validating model predictions. As a pilot project, the company is advancing a drug against desmoid tumors.
3
Country: USA | Funding: $220M
Soley Therapeutics has developed a platform that uses computer vision to capture the response of living cells to drug stress, transforming image characteristics into structured data and uses AI to distinguish drug activity from toxicity, identify mechanisms of action, identify pathways for new drug discovery. Computer vision recognizes features invisible to the human eye that result from a variety of intracellular events, such as protein movement, localization, expression and organelle and membrane dynamics. The company's automated infrastructure enables the screening of over 100,000 compounds per week. The company's first drugs have demonstrated high preclinical efficacy in both hematological and solid tumors. They are also being tested for the treatment of neurodegenerative diseases, obesity/metabolic diseases and hair regeneration.
Soley Therapeutics has developed a platform that uses computer vision to capture the response of living cells to drug stress, transforming image characteristics into structured data and uses AI to distinguish drug activity from toxicity, identify mechanisms of action, identify pathways for new drug discovery. Computer vision recognizes features invisible to the human eye that result from a variety of intracellular events, such as protein movement, localization, expression and organelle and membrane dynamics. The company's automated infrastructure enables the screening of over 100,000 compounds per week. The company's first drugs have demonstrated high preclinical efficacy in both hematological and solid tumors. They are also being tested for the treatment of neurodegenerative diseases, obesity/metabolic diseases and hair regeneration.
4
Country: USA | Funding: $30M
Converge helps pharmaceutical and biotech companies accelerate drug development using generative AI trained on molecular data. The startup trains generative models on DNA, RNA, and protein sequences. The generative model generates new antibodies, then predictive models filter these antibodies based on their molecular properties. Finally, docking system, using physical model, simulates the 3D interactions between the antibody and its target. In addition to the antibody design system, the startup has also introduced models for optimizing protein yield and one for biomarker and target discovery.
Converge helps pharmaceutical and biotech companies accelerate drug development using generative AI trained on molecular data. The startup trains generative models on DNA, RNA, and protein sequences. The generative model generates new antibodies, then predictive models filter these antibodies based on their molecular properties. Finally, docking system, using physical model, simulates the 3D interactions between the antibody and its target. In addition to the antibody design system, the startup has also introduced models for optimizing protein yield and one for biomarker and target discovery.
5
Country: Switzerland | Funding: $2.5B
Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. It is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas.
Roivant’s mission is to reduce the time and cost of developing new medicines for patients and to share those savings with the healthcare system. It is a unique biopharmaceutical company with world-class drug development experts working across multiple clinical and functional areas.
6
Country: USA | Funding: $2.3B
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.
Revolution Medicines is developing new therapies through an innovative approach that harnesses the complex chemicals of life by reconfiguring natural substances into best-in-class medicines.
7
Country: USA | Funding: $1.6B
Arrowhead Research is focused on developing, commercializing, and licensing a range of nanotechnology products and applications.
Arrowhead Research is focused on developing, commercializing, and licensing a range of nanotechnology products and applications.
8
Country: USA | Funding: $1.4B
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
Relay therapeutics is a developer of an allosteric drug-discovery platform intended to apply computational techniques to protein motion.
9
Country: USA | Funding: $1.1B
Eikon is pioneering a new method of drug discovery based on tracking and measuring the movement of individual proteins in living cells.
Eikon is pioneering a new method of drug discovery based on tracking and measuring the movement of individual proteins in living cells.
10
Country: USA | Funding: $1B
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence.
Xaira Therapeutics is an integrated biotechnology company driving advances in artificial intelligence.
11
Country: USA | Funding: $865.4M
Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
Recursion Pharmaceuticals is a digital biology company, developing a drug discovery platform and pipeline with machine learning.
12
Country: USA | Funding: $743M
Insitro is a machine-learning driven drug discovery and development company.
Insitro is a machine-learning driven drug discovery and development company.
13
Country: USA | Funding: $700M
Odyssey Therapeutics is a computational immunology company that develops novel therapeutics for patients with autoimmune diseases.
Odyssey Therapeutics is a computational immunology company that develops novel therapeutics for patients with autoimmune diseases.
14
Country: USA | Funding: $694.1M
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity.
IDEAYA is an oncology-focused biotechnology company committed to the discovery of breakthrough synthetic lethality medicines for genetically defined patient populations and immuno-oncology therapies targeting immuno-metabolism and innate immunity.
15
Country: USA | Funding: $693M
Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.
Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines.
16
Country: USA | Funding: $646M
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines.
Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines.
17
Country: UK | Funding: $601.7M
Isomorphic Labs provides AI-driven solutions for drug discovery and development.
Isomorphic Labs provides AI-driven solutions for drug discovery and development.
18
Country: USA | Funding: $569.1M
Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various monogenic and infectious diseases with unmet medical needs.
Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered zinc finger DNA-binding proteins (ZFPs) as novel ZFP Therapeutics targeting various monogenic and infectious diseases with unmet medical needs.
19
Country: USA | Funding: $530.3M
FogPharma creates a new class of medicines that target human disease drivers currently considered undruggable.
FogPharma creates a new class of medicines that target human disease drivers currently considered undruggable.
20
Country: USA | Funding: $529.9M
Enveda Biosciences is a biotechnology company engineering new drugs from plants.
Enveda Biosciences is a biotechnology company engineering new drugs from plants.
